INTRODUCTION
The eukaryotic nucleus is encased in the nuclear envelope (NE), a structure consisting of the outer nuclear membrane, the inner nuclear membrane and the underlying nuclear lamina (1) . Lamins are type V intermediate filaments that form the proteinaceous network underlying the nuclear lamina. There are several lamin isoforms, including A-type lamins (lamin A, C, AD10 and C2), encoded by the LMNA gene and the lamins B1 and B2, each encoded by its own gene. More than 250 different mutations have been identified in the LMNA gene which result in disorders termed the laminopathies with a broad range of tissue-specific phenotypes affecting nerves, fat, bone and muscle, and include Hutchinsons-Gilford Progeria, lipodystrophies, dilated cardiomyopathy and Emery-Dreifuss muscular dystrophy (2, 3) .
Mutations within the LMNA gene affecting skeletal and cardiac muscles are usually autosomal-dominant missense mutations and lead to Limb-Girdle muscular dystrophy type 1B (LGMD-1B) (4), autosomal-dominant Emery -Dreifuss muscular dystrophy (AD-EDMD) (5), congenital muscular dystrophy (6) and dilated cardiomyopathy with conduction defect (DCM-CD) (7) . Notably, in man, loss of A-type lamins is embryonic lethal and characterized by pre-term death due to respiratory insufficiency, growth retardation, dysmorphic face, severe joint contractures and severe generalized muscular dystrophy with loss of fibers in intercostal muscles (8) . Although the exact mechanisms by which mutations in lamins result in the varied clinical features remain to be elucidated, increasingly compelling evidence suggests that lamins play an important role in regulating nucleoplasmic positioning of chromatin and nuclear shuttling of proteins, and these activities are mediated by interactions between lamins and integral and associated NE proteins (9) . Thus, the characterization of tissue-specific lamin-binding proteins may elucidate the clinical pathogenesis of different mutations within the LMNA gene.
Several animal models of laminopathies have now been developed (10, 11) . Complete deletion of the murine Lmna gene results in muscle weakness and progressive wasting, dystrophy in the peri-vertebral and femoral muscles, irregular fiber diameters, degeneration of the cardiac muscle and death at 4 -6 weeks (12) . Lmna 2/2 muscle cells have been shown to have irregular transcriptional activity and, by electron microscopy, to display nuclear atypia including the redistribution of heterochromatin from the nuclear periphery to the nucleoplasm (13) . Mice heterozygous for the complete deletion are overtly normal but show AV conduction defects by 1 year of age (14) . Several point mutations within the Lmna locus that cause disease in man have also been created in the mouse. These mutations include H222P, which exhibits muscular dystrophy, and N195K, which shows skeletal muscle pathology and cardiomyopathy with a lifespan of 3 -6 months (15, 16) .
Skeletal muscle contains a population of resident stem cells, termed satellite cells, responsible for postnatal muscle growth, hypertrophy and repair (17, 18) . We have recently shown that bone morphogenic protein signaling operating through Smad4 and Smad1, 5 and 8 controls the balance between satellite cell proliferation and differentiation (19) . An important function of lamin A/C is to regulate nucleoplasmic shuttling of Smad transcription factors, particularly those activated by TGFb1 signaling (20) . TGFb1 is a pleiotropic cytokine expressed in many cell types and involved in mediating cell proliferation and differentiation. Canonical TGFb1 signaling activates Smad2/3 transcription factors through complex phosphorylation cascades. Upon activation, Smad2/3 translocate from the cytoplasm to the nucleus and transcriptionally activate gene targets (21) . Recently, Smad2/3 have been implicated in the regulation of muscle growth and differentiation. Smad2/3 are expressed in myoblasts (MBs) and are activated in response to myostatin signaling to suppress the activity of muscle-specific transcription factors such as MyoD (22) . However, muscle-specific deletion of Smad4 and complete ablation of Smad3 result in defective muscle formation (23, 24) , indicating that Smad2/3 play a complex yet important role in muscle development.
A-type lamins also interact with other NE proteins including lamina-associated polypeptides (LAPs), a family of proteins that are integral to the NE. The LAP family member lamina-associated polypeptide 2 alpha (LAP2a) is nucleoplasmic as it lacks a transmembrane domain and interacts with nucleoplasmic lamin A/C. Mutations in LAP2a cause autosomal-dominant DCM, featuring negative coronary angiogram and dilation of the left ventricle (25) . Mice deficient in Lap2a (Lap2a 2/2 ) are viable and fertile. However, cells derived from Lap2a 2/2 mice are hyperproliferative due to defects in cell cycle exit (26, 27) . Therefore, gene ablation of Lap2a in Lmna 2/2 mice could ameliorate their phenotype sufficiently to offer a therapeutic strategy.
Here, we set out to investigate the functional relationship between lamin A/C, Lap2a and Smad2/3 signaling. We found defective postnatal muscle growth in Lmna 2/2 mice, which was accompanied by reduced satellite cell proliferation. Crucially, Lmna 2/2 satellite cells showed upregulated Lap2a and pRb signaling. Since A-type lamins interact with Lap2a and pRb to regulate cellular proliferation, we determined whether downregulating Lap2a could ameliorate the proliferation defect. Lmna 2/2 Lap2a 2/2 mice had increased lifespan and body weight compared with Lmna 2/2 mice and enhanced satellite cell proliferation. Lmna 2/2 MBs also exhibited increased Smad2/3 levels, which was abnormally distributed in the cell and failed to respond correctly to TGFb1 stimulation. However, inhibiting Smad3 signaling by use of a specific inhibitor reduced cell death and augmented MB fusion. Together, our results show that perturbed Lap2a/pRb and Smad2/3 signaling are important regulatory pathways mediating defective muscle growth in Lmna 2/2 mice, and that inhibition of either pathway alone or in combination can ameliorate this deleterious phenotype.
RESULTS

Lmna
2/2 mice form smaller muscle fibers
We have previously shown that muscle fibers from Lmna 2/2 mice contain fewer myonuclei per myofiber than wild-type (WT) (13) , suggesting defective growth of Lmna 2/2 muscle during early postnatal development (up to 3 weeks) when myonuclei are added (28) . To study the dynamics of postnatal muscle growth, we conducted histological analysis of gastrocnemius muscle from Lmna 2/2 and WT mice at 3 weeks of age (Fig. 1A) . In WT muscle, diameters ranged from 20 to 100 with the highest percentage of myofibers (mode) lying in the 41-45 mm range. In Lmna 2/2 mice, however, the range of myofiber diameters remained from 16 to 80 mm and the myofibers were generally smaller with a shift in distribution to a mode lying in the 35-40 mm range (Fig. 1B  and C ). In addition, we performed a BrdU dilution assay in which postnatal mice are treated with BrdU to label proliferating cells. In WT mice, BrdU label got diluted over time, while over the same time in Lmna 2/2 mice, the proportion of BrdU+ve cells remained high, indicating that less dilution has occurred and thus activation or proliferation is decreased (Supplementary Material, Fig. S1 ).
Satellite cell-derived myoblasts from Lmna 2/2 mice show delayed activation and proliferate at a slower rate than WT
LGMD1B and AD-EDMD are muscle-wasting diseases, which, together with our observation of smaller muscle fibers in the mouse model, suggested that loss of lamin A/C may interfere with the ability of satellite cells to contribute myonuclei. We examined proliferation of satellite cell-derived MBs ex vivo using cultured myofibers isolated from extensor digitorum longus (EDL) muscle. This preparation serves as a model of the satellite cell activation that occurs in response to injury in vivo (29) . Isolated muscle fibers were cultured for 24 h in the presence of 5-ethynyl-2 ′ -deoxyuridine (EdU), (29) . When grown under proliferating conditions, Lmna 2/2 H-2K MBs still proliferated 30% slower than WT H-2K MBs (n ¼ 3 clones; P , 0.001) (Fig. 2C) . Thus, immortalization by large T antigen produces MB cell lines that exhibit ex vivo proliferation rates characteristic of the genotype of the mouse from which the cells were isolated. mice. Cells were plated at a low density (5000 cells/cm 2 ) in growth medium, which was replaced after 24 h with lowserum differentiation medium. Under these conditions, the majority of cells withdraw from the cell cycle, but a small proportion continued to proliferate (data not shown). After 5 days of culture, WT MBs efficiently differentiated into myotubes, as shown by immunostaining for myosin heavy chain and counterstaining with DAPI, but Lmna 2/2 cultures contained fewer cells and in turn formed fewer myotubes (Fig. 2D -F) . To determine whether decreased fusion into myotubes in Lmna 2/2 cultures was due to an inherent inability to differentiate and fuse, or due to the slower proliferation rate, we plated the cells at a high density (28 000 cells/cm 2 ), and immediately switched them into low-mitogen medium to promote cell cycle exit and myogenic differentiation. Under such conditions, both WT-and Lmna 2/2 -derived MBs efficiently formed myotubes ( Fig. 2Ga and b) , indicating that Lmna 2/2 MBs at low density form fewer myotubes because they proliferate more slowly, not because they are defective in fusion. However, the myotubes formed by Lmna 2/2 MBs showed abnormal myonuclear morphology, for example, having chromatin strands that protruded between neighboring nuclei ( Fig. 2Ga ′ and b ′ ). These data are consistent with earlier findings that Lmna 2/2 MBs do not show an inherent inability to differentiate and form myotubes (33) , but indicate that the reduced proliferation can result in decreased myotube formation.
Nuclear abnormalities destabilize nuclear localization of transcription factors in Lmna 2/2 muscle cells
Mutations in lamin A can result in defective targeting and retention of nuclear proteins (34) . To determine whether abnormal nuclear protein retention influences localization of transcription factors, we examined expression of MyoD, myogenin and pRbS780 in Lmna 2/2 myotubes by immunostaining. We found nuclear abnormalities including mislocalization of MyoD and myogenin and protruding chromatin strands between adjoining nuclei, with MyoD and myogenin sometimes co-localizing with these chromatin strands. In particular, some nuclei were devoid of MyoD/myogenin immunostaining, whereas others contained MyoD/myogenin but had low/negligible DAPI staining, indicating low levels of chromatin. In addition, we found mislocalized pRbS780 (Fig. 2H ). These data suggest that defective nuclear targeting and retention of proteins in Lmna 2/2 muscle cells result in misregulated localization of transcription factors activated during myogenesis.
Quantitative proteomic analysis of Lmna 2/2 myoblasts and myotubes
To identify differences in protein expression between WT and Lmna 2/2 , we performed stable isotope labeling by amino acids in cell culture (SILAC) quantitative proteomic profiles of proliferating H-2K MBs and differentiated H-2K myotubes. In this approach, proliferating cells are cultured in the presence of lysine and arginine labeled with 13 C ('heavy') or Human Molecular Genetics, 2013, Vol. 22, No. 14 2855 normal 12 C ('light'). The presence of 'heavy' labeled amino acids causes a shift in the mass spectra of signature peptides and the different intensities of the peaks were used to obtain relative quantities in Lmna 2/2 compared with WT samples (Fig. 3A) . In MBs, 1103 proteins were identified of which 39 were downregulated and 201 were upregulated .1.5-fold compared with WT. In myotubes, we identified 979 proteins of which 295 were downregulated and 156 were upregulated .1.5-fold (Fig. 3B ).
Downregulated MyoD targets in Lmna 2/2 myoblasts
In Lmna 2/2 proliferating MBs, decreased proteins included MYH4, MYL1, MYL4, TNNT1 and TNNT3 (Supplementary Material, Table S2 ), indicating that myogenesis is compromised in Lmna 2/2 muscle cells. Proteins identified in the SILAC analysis could be targets of activated or inhibited transcription factor pathways. Ingenuity Pathway Analysis (IPA) was used to identify transcriptional activators that were misregulated in Lmna 2/2 MBs compared with WT ( Fig. 3C ). The top downregulated myogenesis-associated transcription factors were MyoD (activation z-score 21.88, P ¼ 8.57 E208) and E2F1 (z-score 22.466, P ¼ 1.21E210), whereas the top transcriptional activator pathways involved in myogenesis that were upregulated were retinoblastoma (Rb, z-score ¼ 1.62, P ¼ 7.29 E24) and Smad3 (z-score ¼ 3.2, P ¼ 1.6 E23) (Fig. 3C ).
The Smad2/3 transcription factor pathway is upregulated in Lmna 2/2 myoblasts A-type lamins have been implicated in regulating the transcriptional activity of Smad2/3, a signaling pathway important for proliferation, differentiation and cell death (20) . Smad2/3, (36), and decreases the transcriptional activity of MRFs without affecting their binding properties, by targeting the bHLH region (37) . Furthermore, Smad3 but not Smad2 physically interacts with MyoD, inhibiting its transactivation properties (38, 39) . Our proteomic analysis revealed that Smad3 transcriptional targets were significantly upregulated in Lmna 2/2 MBs (P ¼ 1.6E-3) (Fig. 3C ). Among the upregulated proteins were Col2A1, Col1A2, TPM1 and TPM2, known targets of Smad3 (Supplementary Material, Table S2 ). These data suggest that upregulated Smad3 signaling may have an impact on myogenesis. Interestingly, we also found upregulated Smad3 signaling in Lmna 2/2 myotubes, and again increased Col2A1, Col1A2, TPM1 and TPM2 (Supplementary Material, Excel file MT).
To address the role of Smad2/3 signaling in Lmna 2/2 muscle cells, we examined the nucleo-cytoplasmic shuttling of these factors during differentiation. Upon TGFb1 receptormediated activation, Smad2/3 become phosphorylated and translocate to the nucleus to transactivate transcription targets, following which, Smad2/3 become dephosphorylated by protein phosphatase 2A and are exported back to the cytoplasm (18) . Thus, activated Smad2/3 are localized to the nucleus, whereas inactive Smad2/3 are cytoplasmic. In proliferating cells, Smad2/3 are activated and thus localized to the nuclei where they repress activation of muscle genes such as MyoD. In contrast, during differentiation, Smad2/3 become inactive and localize to the cytoplasm (39) . Western blot analysis showed that the total expression of Smad2/3 was increased in both nuclear and cytoplasmic fractions of Lmna 2/2 muscle cells compared with WT (Fig. 4A) . We assessed activation of Smad2/3 by quantifying the ratio of nuclear to cytoplasmic concentration during the stages of myotube differentiation (Fig. 4B) . In WT cells, the activated (nuclear) Smad2/3 peak at the onset of differentiation (days 1 to 2), then become more cytoplasmic (inactive) on days 3 to 4, consistent with published reports (37) . In Lmna 2/2 muscle cells, however, Smad2/3 activity remained upregulated (nuclear) throughout differentiation (days 1 -4) (Fig. 4B) . MBs.
Treatment of WT MBs with 1 ng/ml TGFb1 increases cellular proliferation, increases total cell number and decreases differentiation compared with non-treated MBs (unpublished data). We determined the response to TGFb1 treatment in Lmna 2/2 primary satellite cells. In untreated WT MBs, immunostaining revealed that Smad2/3 localized to the nuclei, but in myotubes nuclear localization was reduced (Fig. 4C) , consistent with our western blot analysis. Treatment with TGFb1 caused Smad2/3 to localize to the nuclei of both MBs and myotubes in WT. In untreated Lmna 2/2 MBs, total expression of Smad2/3 was generally upregulated but localization was less clearly nuclear even after treatment with TGFb1 (Fig. 4C ). These data suggest that retention of Smad2/3 is challenged in the nuclei of Lmna 2/2 muscle cells, making them less able to respond to TGFb1 stimulation, and we suggest that this results in compensatory upregulation of Smad2/3 signaling, which we were able to show by western blot (Fig. 4A ). These data suggest that defective shuttling of Smad2/3 in Lmna 2/2 muscle results in compensatory activation of Smad2, and especially Smad3. Therefore, a loss of lamin A/C in muscle perturbs Smad2/3 nuclear transport, resulting in compensatory Smad3 target gene upregulation.
Blockade of Smad3 decreases cell death in Lmna 2/2 myotubes AD-EDMD is characterized by muscle atrophy and necrosis (40) . Since in addition to regulating cell proliferation, Smad2/3 play a role in regulating cell viability, we next determined whether the increased Smad2/3 activity exacerbates death of Lmna 2/2 myotubes. We examined cell death in myotube cultures using a calcein and EthD-1 permeability assay (LIVE-DEAD) (Fig. 4D) Fig. S2 ). When Lmna 2/2 MBs were differentiated in the presence of 5 mM SIS3, cell death was significantly ameliorated from 22.3 + 1.5% to 15.0 + 1.0% (mean + SEM; n ¼ 3 experiments; P , 0.05) (Fig. 4E) .
Consistent with this observation, IPA of the proteomic myotube data identified upregulated expression of 14 proteins associated with cell death (Supplementary Material, Table S3 , Supplementary Material, Excel MT). Of these, we identified mediators of cell death which were also direct targets of Smad2/3, with TPP1, RTN4 and BCL12L13 upregulated in Lmna 2/2 myotubes (Fig. 4F ). These observations suggest that upregulation of Smad3 results in muscle wasting in Lmna 2/2 , and blocking Smad3 promotes survival. Whereas Smad3 signaling is important in mediating the maintenance of Lmna 2/2 myotubes, Smad3 signaling alone did not appear to explain the proliferation defect we observed in muscle and primary satellite cells.
We also identified several misregulated targets of pRb/E2F1 signaling in our screen, including DHFR, ERH, VIM and COL2A1 (Supplementary Material, Table S3 ). This is consistent with our data on the perturbed cell cycle dynamics in Lmna 2/2 satellite cells: pRb is a transcriptional repressor that, when hypo-phosphorylated (activated), represses E2F1-dependent transcription of cell cycle gene targets, in turn, allowing MBs to exit the cell cycle and differentiate. Alternatively, hyper-phosphorylated pRb does not repress E2F1 and proliferation ensues (41) . Consistent with these observations, we found that pRbS780 is reduced and/or mislocalized in Lmna 2/2 cells (Fig. 2H ), indicating that pRb is an activated hypo-phosphorylated state resulting in decreased E2F1-mediated transcription and, in turn, decreased proliferation. We further quantified this using western blot analysis. We found a modest decrease in phospho-pRb, indicative of activation, in proliferating Lmna 2/2 primary cells compared with WT ( Fig. 5A and B ) and decreased total pRb in both proliferating MBs and differentiated myotubes. These data indicate that pRb is deregulated in Lmna 2/2 muscle cells. Nucleoplasmic lamin A/C interacts with pRb in a complex with lamina-associated polypeptide alpha (Lap2a) that maintains pRb in an activated state and allows cell cycle exit (42, 43) . Since pRb signaling was misregulated in Lmna
MBs, we next focused on the role of Lap2a in regulating MB cell cycle in the absence of lamin A/C. (Fig. 5C) , and was consistent with previous reports (33) . A loss of Lap2a results in disruption of the lamin A/ C-pRb-Lap2a complex, and cells lacking Lap2a do not exit cultures (P , 0.001), and not significantly different from WT (P ¼ 0.24) (Fig. 6E) . These data suggest that loss of Lap2a in Lmna 2/2 cells restores the number of satellite cells per colony to WT levels, indicating a re-balancing of cell cycle dynamics. (Fig. 6C , quantified in F). Whereas the fusion index in satellite cells cultured from Lmna 2/2 mice was significantly lower than WT, the index was restored to WT levels in satellite cell cultures from Lmna 2/2 Lap2a 2/2 , reflecting the enhanced proliferation (Fig. 6F) . Furthermore, proteomic analysis of Lmna Table S2 , Fig. 6G ). We validated these proteomic analysis findings by measuring the expression of these genes in primary satellite cells. A quantitative reverse transcriptionpolymerase chain reaction (qRT -PCR) showed similarly reduced expression of these genes in Lmna 2/2 primary satellite cells and myotubes, compared with WT. In contrast, expression of Myh1 and Myl6b was restored to WT levels in Lmna 2/2 Lap2a 2/2 MBs and myotubes (Fig. 6H ). These data suggest that reduction of Lap2a can partially rescue the myogenic deficiency associated with the lack of lamin A/C. -d4) . Cell pellets were separated into nuclear (n) and cytoplasmic (c) fractions and subjected to immunoblotting using antibodies to Smad2/3. Vinculin was used as a loading control. (B) Quantitation of Smad2/3 in nuclear and cytoplasmic fractions. Values greater than 0.5 indicate a predominantly nucleoplasmic localization (n ¼ 3 experiments per time point + SEM). (C) WT and Lmna 2/2 satellite cells were incubated with differentiation medium containing 10 ng/ml of TGFb1 for 54 h, then immunostained with antibodies to Smad2/ 3 (green) and desmin (red) and co-stained with DAPI (blue) to visualize nuclei. In untreated WT cells, some Smad2/3 expression can be seen in the nuclei of MBs whereas nuclear localization is decreased in myotubes. In response to treatment with TGFb1, Smad2/3 localize to the nuclei of both MBs and myotubes (green). In Lmna 2/2 cells, Smad2/3 are generally upregulated but localization is equally distributed in nuclear and cytoplasmic compartments. MBs in the presence of the Smad3 inhibitor SIS3, and immunostained cultures for MHC (Fig. 7A) . Treatment with SIS3 significantly increased the size of myotubes from a mean + SEM of 9.14 + 1.32 to 20.15 + 3.73 nuclei/myotube in Lmna 2/2 cultures (Fig. 7B) . Interestingly, treatment with SIS3 also increased the size of myotubes in WT and Lmna
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2/2 , suggesting that inhibiting Smad3 during differentiation has the added effect of further increasing muscle growth. As the effect on Lmna 2/2 Lap2a 2/2 was cumulative, the data MBs. WT and Lmna 2/2 muscle cells were collected at different timepoints: proliferating MBs and days 1-4 of differentiation (d1-d4). Cell pellets were separated into nuclear and cytoplasmic fractions and subjected to immunoblotting using antibodies to Lap2a and lamin A. Vinculin was used as a loading control. (D Figure 8 .
DISCUSSION
A-type lamins interact with pRb/Lap2a and Smad3 to mediate muscle formation and maintenance Nuclear lamins function by providing structure to the nucleus as they form a scaffold connecting the nucleoplasm through the NE LINC complex to the cytoplasm (44) . The scaffold is formed through interactions with a growing number of identified NE and nucleoplasmic proteins. Bioinformatic analysis by use of the database analysis software STRING 9.0 and reports by others show that this list includes SYNE1, EMD, LEMD3, LAP2a, pRb, SREBP1 and Smad3 (Supplementary Material, Fig. S3 , (45,46, reviewed in 47) . Because these interactions further influence the tethering of transcriptionally inactive heterochromatin to the nuclear periphery, they form the basis of the so-called 'lamin hypothesis' which postulates a role for lamin A/C and related proteins in the control of gene expression. The interactions between lamin A/C and the other binding partners are determined by the tissue-specific nature of their expression and thus explain how so many different mutations within the LMNA gene can result in the broad spectrum of phenotypes observed in the laminopathies (2) .
Here, we focused on the muscle phenotype resulting from the absence of lamin A/C. We describe for the first time the cultures were derived from WT, Lmna 2/2 , Lap2a 2/2 and Lmna 2/2 Lap2a 2/2 mice. After 72 h, cell numbers in the satellite cell colonies were quantified and are shown + SEM (n.100 colonies/mouse, from at least 3 mice/genotype). Lmna role of the satellite cell in striated muscle forms of the laminopathies by showing delayed activation and decreased proliferation of primary and immortalized MBs from Lmna 2/2 mice and defective postnatal growth of these animals. Based on our in vivo analysis of muscle fiber diameters, the dilution of BrdU label, reduced numbers of Pax7+ve/EdU+ve fiberassociated satellite cells, and our in vitro analysis of primary and immortalized Lmna 2/2 satellite cells, we conclude that decreased proliferation contributes to a decreased myofiber size in Lmna 2/2 mice. Our data are consistent with reports of human diploid fibroblasts lacking LMNA, which grow slowly in culture (48) , senesce prematurely (49) and exit from the cell cycle (41) . This also parallels the premature senescence that was observed in adult fibroblasts from progeroid mice harboring a deletion within exon 9 of the lamin A/C gene (50) . On the other hand, our observations in primary satellite cells and T antigen-immortalized MBs conflict with a report of increased proliferation in paw epidermis of Lmna 2/2 mice (26) and increased proliferation of Lmna 2/2 expanded and selected spontaneously immortalized MBs (51). It is possible that lamins A and C have a different activity in embryonic tissues and/or undifferentiated cells, which would help explain why Lmna 2/2 mice are not smaller than littermates at birth. Thus, A-type lamins appear to play a complex role in cell cycle regulation that may lead to different phenotypes in different tissues and is dependent on the differentiation stage. In this respect, it is of importance that our examination of muscle sections, myofiber-associated satellite cells and of primary MB cultures is consistent with the small size of Lmna 2/2 mice and muscle, as well as muscle weakness and myopathy in AD-EDMD and LGMD1B patients.
We further used quantitative proteomics to identify MyoD, pRb and Smad2/3 as the main transcription factor pathways misregulated in Lmna 2/2 muscle. Based on our findings, we propose that at least two separate processes undermine muscle growth and maintenance in the absence of lamin A/ C. In activated satellite cells, A-type lamins interact with Lap2a and pRb to control proliferation and self-renewal. In proliferating cells, where pRb is phosphorylated, pRbS780 does not repress E2F1-dependent transcriptional activation, allowing the cell cycle to proceed. One such target identified by our proteomic analysis is ribonucleotide reductase M1, important for DNA synthesis during S-phase (52), which was downregulated in Lmna 2/2 cells (Supplementary Material, Table S2 ). These interactions allow activation of E2F1, which maintains the proliferating cell in the cell cycle.
In addition, Smad3 is inhibitory for myotube differentiation; thus the combined compensatory upregulation of pRb/Lap2a and Smad3 in Lmna 2/2 results in decreased satellite cell activation, as shown by delayed expression of MyoD and myogenin, decreased MB proliferation and decreased expression of muscle-specific genes-Myh1, Myh4 and Myl6b. While MB proliferation is affected in Lmna 2/2 , resulting in fewer muscle cells and myofibers formation, our data show that the process of myofusion in itself is not affected, as MBs plated at high density efficiently fused into myotubes and muscle fibers form in mice. Although our proteomic profiling data do not establish a causative relationship, others have demonstrated that TGFb1 induces cell cycle arrest by initiating the recruitment of a complex consisting of Smad2/3, phosphorylated pRb and E2F4 (53) , suggesting that this complex may also be active in proliferating MBs, as summarized in our model (Fig. 8) . Interestingly, a common target of both pRb and Smad3 pathways, Col2A1, was shown to be upregulated in Lmna
. Col2A1 is negatively regulated by E2F1 (54) . In addition, Col2A1 transcription is activated by Smad3 (55). Thus, a potential complex forming between Smad2/3 and pRb could play a role in Lmna 2/2 cells.
Smad2/3 signaling could be upregulated to compensate for loss of responsiveness to TGFb1
TGFb1 increases MB proliferation and prevents exit from the cell cycle while simultaneously inhibiting myogenesis by promoting the degradation of MyoD and decreasing myogenin, troponin and MHC expression (56) . TGFb1 also suppresses Figure 8 . Hypothetical model of lamin A/C interactions. In WT activated satellite cells, levels of Smad3 remain low. Proliferation is driven by nucleoplasmic lamin A/C/Lap2a/pRb complexes which prevent pRb from repressing cell cycle gene activation by E2F1. MyoD increases in differentiating cells resulting in myotube formation. In the absence of lamin A/C, there is compensatory upregulation of Smad3, which represses MyoD. In addition, Smad3 potentiates pRb, which represses E2F1 and also inhibits MyoD activity, including transcriptional activation of MYH1, MYH4 and MYL6b. As a result, cell proliferation is decreased and in turn results in smaller muscle being formed. During the maintenance of the myofiber, upregulated Smad3 signaling in Lmna 2/2 leads to cell death and muscle wasting, including upregulated cell-death related proteins TPP1, RTN4 and BCL2L13.
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Human Molecular Genetics, 2013, Vol. 22, No. 14 expression of Sca-1 that may be required for satellite cell activation, and as a result, stem cell-like MB populations are maintained (57, 58) . Our finding of upregulated Smad2/3 in Lmna 2/2 MBs suggests that the muscle defect arising from decreased proliferation is, in part, due to misregulated Smad2/3 signaling. An interaction between lamin A/C and Smad2/3 has previously been proposed in fibroblasts. Lamin A/C were shown to interact with protein phosphatase 2A required for nuclear export of Smad2/3 (20) . An indirect connection between lamin A/C and Smad2/3 may also arise via the common binding partner Man1/Lemd3 (59; reviewed in 60). On the other hand, proteomic analysis of Smad3 co-immunoprecipitates identified lamin A/C as a direct binding partner of Smad3 (45) . Lamins A and C have been shown to regulate general nuclear protein import (34) and localization of NE proteins including emerin and Lap2a (12) . Thus, total loss of lamin A/C would be predicted to result in mislocalization of many nuclear proteins including Smad3 and other transcription factors involved in myogenesis.
In addition to disrupting proliferation and myogenesis in Lmna 2/2 muscle, upregulated Smad3 signaling results in transcription of cell death-associated proteins such as TPP1, RTN4 and BCL2L13, leading to muscle wasting (Fig. 8) . Importantly, blocking Smad3 using the specific inhibitor SIS3 promoted both myogenesis and muscle maintenance, as evidenced by both decrease in cell death and increase in myotube size, suggesting that muscle wasting in laminopathies could be improved by TGFb1 inhibition.
Partial rescue of Lmna 2/2 phenotype by loss of Lap2a Lmna 2/2 mice survive postnatally for 4 -6 weeks and show pathologies including myopathy, cardiomyopathy, sarcopenia, osteopenia, decreased bone formation, neuropathy and abnormal neuromuscular junctions (12, (61) (62) (63) (64) . A gene-trap mutation in the Lmna locus was reported to show a similar phenotype with decreased myofiber diameters and cardiac defects (65) . Cardiac conduction defects and myopathy were also described in mice that are heterozygotes for loss of lamin A/C (14), as well as homozygous mice carrying the H222P mutation in the Lmna locus (16) . Recently, expression of a lamin A/C transgene under a cardiac-specific MHC promoter in Lmna 2/2 mice improved lifespan by 12% (66) . These reports support the notion that a cardiac defect is a major contributor to death in Lmna 2/2 mice. Our observation of premature cell cycle arrest in Lmna 2/2 satellite cells correlates with upregulated Lap2a, deregulated pRbS780 and decreased E2F1 transcription. In view of the reported involvement of Lap2a in pRb-mediated cell cycle arrest, this may be the cause of the proliferation defect in Lmna 2/2 satellite cells. Alternatively, the cell cycle phenotype may arise from loss of lamin A/C, leading to mislocalization of Lap2a/pRb/E2F1 complexes and/or their binding to chromatin. Here, we have shown that loss of Lap2a in Lmna 2/2 mice led to a 30% increase in survival rate and a 25-50% increase in body weight. As loss of Lap2a was not sufficient to completely rescue the Lmna 2/2 phenotype, we speculate that the cardiac defect was still the primary cause of death in both Lmna 2/2 and Lmna 2/2 Lap2a 2/2 mice. However, the data implicate arrested growth as another likely contributor to the reduced lifespan in Lmna 2/2 mice, such that Lap2a deficiency promoted increased proliferation leading to increased perinatal growth and increased muscle mass, that in itself favors longer survival, perhaps by improving their ability to suckle and feed postnatally.
The observation that Lap2a protein levels are higher in the absence of lamin A/C is paralleled by a recent finding that lamin A loss and progeric LMNA mutations also result in increased Sun1 protein levels, leading, in this latter case to redistribution of Sun1 protein from the NE to the Golgi where it may disrupt Golgi function (67) . This parallel extends to the observation that genetic ablation of Sun1 significantly increased longevity and weight gain and ameliorated the muscle and cardiac pathology associated with the loss, or mutation, of lamin A. Although we have not looked at Lap2a distribution (or accumulation/turnover) in our Lmna 2/2 cells, the fact that Lap2a protein levels are increased suggests that a common molecular mechanism of excess NE-or lamin-associated protein accumulation may underlie the pathology associated with a loss of lamin A.
A-type lamins exert their activity by promoting formation of complexes that mediate transcription of key genes involved in regulating cellular functions. We have provided here at least two distinct mechanisms by which lamins A and C contribute to growth and maintenance of skeletal muscle, through direct or indirect complexes with pRb/Lap2a and Smad3, respectively. Taken together, our observations shed light on the range of molecular mechanisms involved in laminopathies and open the way toward potential new therapeutic approaches.
MATERIALS AND METHODS
Mice
Lmna
2/2 mice were previously described (12 (26) and maintained as heterozygous intercrosses. All mice were maintained according to Children's National Medical Center IACUC guidelines. Mice were euthanized using CO 2 asphyxiation followed by cervical dislocation and muscles were flash-frozen in liquid nitrogen cooled in isopentane.
Single myofiber isolation
Freshly removed EDL muscles were incubated in 0.2% collagenase Type I (Sigma, St Louis, MO, USA) in DMEMGlutaMAX (Life Technologies, Carlsbad, CA, USA) and 1% (v/v) penicillin/streptomycin solution (Sigma) for one and a half hours at 378C. Collagenase was then inactivated and individual myofibers liberated by trituration, as described in detail elsewhere (68) . Myofibers were microscopically examined to ensure that they were free of capillaries or residual connective Human Molecular Genetics, 2013, Vol. 22, No. 14 2865
tissue. Selected myofibers were cultured and fixed for 10 min in 4% paraformaldehyde/PBS (Sigma) at the desired time points.
Myofiber and cell culture
For suspension cultures, myofibers were incubated in DMEMGlutaMAX (Invitrogen), 10% (v/v) horse serum (Invitrogen), 0.5% (v/v) chick embryo extract (US Biological, Swampscott, MA, USA), and 1% (v/v) penicillin/streptomycin solution (Sigma) (plating medium) at 378C in 5% CO 2 . Fiberassociated satellite cells were obtained as previously described (68) . Briefly, isolated myofibers were plated in six-well plates (BD Labware) coated with 1 mg/ml Matrigel (BD Biosciences) in DMEM with 20% (v/v) fetal calf serum (Gibco), 10% (v/v) horse serum (Gibco), 1% (v/v) chick embryo extract (US Biological), 1% (v/v) penicillin/streptomycin solution (Sigma) and 5 ng/ml bFGF (PeproTech) (growth medium), and maintained at 378C in 5% CO 2 . After 72 h in culture, myofibers were removed, and the satellite cell-derived MBs passaged and re-plated in Matrigel-coated culture dishes for further expansion. Satellite cells for clonal cultures were derived as previously described (69) . Briefly, freshly isolated EDL single myofibers (15 -20 per mouse per experiment) from Lmna 2/2 and WT mice were stripped of satellite cells immediately upon isolation by digestion in 0.05% Trypsin/EDTA (Gibco) at 378C for 5 min followed by gentle trituration. Myofiber fragments were removed by passing through a 40 mm cell strainer (BD Falcon), and satellite cells collected. Individual cells were plated in Matrigel-coated 96-well plates (BD Falcon) and maintained in the growth medium described above, without bFGF. The cultures were fixed after 72 h or 96 h, for 10 min in 4% paraformaldehyde/PBS (Sigma), washed with PBS and stained with Blue Coomassie. The number of cells per well (thus, per clone) was then counted using an Olympus CK-2 microscope.
Immortalized satellite cells (H-2K cells) were derived from Lmna 2/2 :T + mice single fibers as described above. Control H-2K cells were derived from WT:T + F2 littermates. H-2K were maintained at 338C in growth medium containing 0.2% IFNg (Millipore) and differentiated at 378C in DMEMGlutaMAX containing 5% horse serum without IFNg (29) . For experimental treatments and immunohistochemistry, MBs were cultured on Matrigel-coated LAB-TEK w eight-well chamber slides (Nunc, Rochester, NY, USA) or glass-bottom culture dishes (MatTek Corporation, Ashland, MA, USA).
Histology and immunofluorescence microscopy
For histology, 10 mm sections were air dried, then stained with hematoxylin and eosin (H&E). Images were acquired using a Nikon Eclipse E800 microscope equipped with a 10×/0.45 and 20×/0.75 objectives and RT Slider Diagnostic SPOT CCD camera using Photoshop (Adobe) acquisition software. Image analysis was performed using ImageJ software (70) and quantified using MinFeret calculation as previously described (71) .
For double labeling with Pax7 and EdU, freshly isolated single fibers were pulsed with EdU for 24 h, then fixed in 4% paraformaldehyde/PBS (Sigma). EdU detection was performed using the Click-iT w EdU AlexaFluor w 594 Imaging kit (Molecular Probes/Invitrogen), according to the manufacturer's protocol. Subsequently, fibers were incubated with an anti-Pax7 antibody (Developmental Hybridoma Studies Bank). Percentage of EdU+ve/Pax7+ve cells was derived by dividing by total number of Pax7+ve satellite cells counted on 50 fibers isolated from three individual mice. In parallel, fibers were immunostained with anti-Pax7 and either anti-MyoD or anti-myogenin antibodies and quantitated as above.
Satellite cells and differentiated myotubes cultured on silanized coverslips were fixed with fresh 4% paraformaldehyde/ PBS (Sigma), blocked with 5% horse serum and 1% bovine serum albumin, then incubated overnight with anti-myosin heavy chain (Developmental Hybridoma Studies Bank); antiMyoD (Novus Biologicals, Littleton, CO); anti-myogenin (Santa Cruz); anti-RbS780 (Abcam, Cambridge, MA, USA). Fluorophore-conjugated secondary antibodies were applied for 1 hour. Cells were treated with TGFb1 (R&D Systems, Minneapolis, MN, USA) using indicated concentrations and incubation times. LIVE-DEADw cytotoxicity assay was performed following manufacturer's instructions (Molecular Probes).
For Smad3 blocking assay, MBs were treated with indicated concentrations of the Smad3-specific phosphorylation inhibitor SIS3 (EMD Biosciences, Billerica, MA, USA) for 5 days, then incubated with LIVE-DEADw cytotoxicity assay reagent or fixed and immunostained using an anti-myosin heavy chain antibody. The myogenic fusion index was calculated as the percentage of nuclei in myotubes relative to total nuclei.
Immunofluorescence micrographs were acquired at ambient temperature using a Zeiss Axiovert 200 inverted microscope equipped with 20×/0.3 and 63×/1.4 objectives and an Axiocam Mrm CCD camera. Images were acquired using Axiovision 4.8.2 software and analyzed using Photoshop and ImageJ software.
Stable isotope labeling In culture (SILAC) proteomics
WT H-2K cells were cultured in 'heavy' (or 'labeled') media in which Arg and Lys were replaced by N 2 -Lys (Sigma-Aldrich). Three biological replicates (H-2K clones) were pooled for each condition. MBs were passaged three times to allow for sufficient incorporation of label. This approach has been found to produce .98% incorporation (72) . At this point, MBs were plated onto Matrigel-covered dishes and cultured for 3 days in growth medium without IFNg before harvesting.
Whole cell lysates were prepared using RIPA buffer containing anti-proteases (Mini-Complete, Roche). Protein concentration of each sample was determined using the Bradford assay (Bio-Rad). Fifty microgram 'labeled' protein was mixed with 50 mg 'unlabeled' protein and separated on a 4 -12% NuPAGE gel (Invitrogen). Gels were stained with Bio-Safe Coomassie (Bio-Rad, Hercules, CA, USA) and
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Human Molecular Genetics, 2013, Vol. 22, No. 14 each lane was sliced into 30 pieces, followed by digestion with trypsin (Promega, Madison, WI, USA) as previously described (73) . Resultant peptides from each band were dried by vacuum centrifugation and resuspended in 6 ml of 0.1% TFA for analysis by mass spectrometry. LC-MS/MS was performed on a hybrid Thermo LTQ-Orbitrap-XL mass spectrometer (Thermo Fisher Scientific, USA) coupled online to a nano-LC system (Eksigent, Dublin, CA, USA) (73) . Proteins were identified from raw MS and MS/MS data using the Sequest algorithm in the Bioworks Browser 3.3.1 software (Thermo Fisher Scientific) against the Uniprot mouse database (UniProt release-2010_11, 16,333 entries) indexed for fully tryptic, 300-4000 mass range, and two missed cleavages.
Database analysis
Protein annotations were acquired using the Keyword and GO terms in the Uniprot Protein Knowledgebase (http://www.unip rot.org/). The molecular mass values and percentage of the protein covered by the matched peptides were retrieved from Bioworks output files. Known contaminant proteins from processing or serum (e.g. keratin, albumin, hemoglobin) were excluded from the analysis. Biological function analysis was performed using UniProt Gene Ontology, DAVID, IPA and STRING 9.0.
Western blotting
Cultured primary MBs were maintained in proliferation or differentiation media for indicated number of days. Nuclear and cytoplasmic fractions were prepared using the NE-PER kit (Pierce) according to manufacturer's instructions. Lysates (10 mg) were loaded onto 4 -12% NuPage Bis-Tris gels (Invitrogen) and transferred onto PVDF membranes. Following blocking in 5% Blocking Grade Reagent (Bio-Rad), membranes were probed overnight with antibodies to Smad2/3 (Cell Signaling), lamin A (Abcam), vinculin (Sigma), actin (Santa Cruz) and pRb (Santa Cruz). The Lap2a monoclonal antibody was previously described (26) . Appropriate secondary antibodies were applied for 30 min and following washes, membranes were developed using ECL reagent (Pierce) and processed on a BioMax film (Sigma).
RNA isolation and real-time analysis
Total RNA was isolated from satellite cells using the RNeasy Mini kit (Qiagen). First-strand synthesis was performed using the First Strand cDNA Synthesis kit (Roche) according to manufacturer's instructions. A qRT -PCR was performed on an ABI 7900HT Fast Real-Time PCR system using an SYBRw Green PCR master mix (Applied Biosystems) and indicated PCR primers (Supplementary Material, M&M Primers). Raw C T values were normalized to S18, HPRT and GAPDH and relative gene expression was obtained using the C T method (74) .
Statistics
Student's t-test was used in all statistical analyses unless indicated otherwise.
SUPPLEMENTARY METHODS
BrdU dilution assay
The thymidine analog 5-bromo-2 ′ -deoxyuridine (BrdU; Sigma) was injected subcutaneously (250 mg/g body weight) into newborn mice during the first 7 postnatal days. Animals were euthanized and quadriceps muscle was harvested on indicated postnatal days. Frozen sections (10 mm) were fixed in ice-cold acetone for 10 min, denatured in 2 N HCl for 1 h, and incubated with 0.15 M sodium borate solution to neutralize before primary antibody incubation.
For BrdU staining, sections were incubated with biotinylated anti-BrdU (MoBU-1, Life Technologies) and anti-laminin (Sigma) antibodies. The following day, sections were incubated for 1 h with FITC-conjugated anti-streptavidin, Marina Blueconjugated goat anti-rabbit antibody (Life Technologies) and propidium iodide (Sigma).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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